These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1276 related articles for article (PubMed ID: 34544114)

  • 1. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
    Schmidt F; Weisblum Y; Rutkowska M; Poston D; DaSilva J; Zhang F; Bednarski E; Cho A; Schaefer-Babajew DJ; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Nature; 2021 Dec; 600(7889):512-516. PubMed ID: 34544114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
    Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
    Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
    Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
    J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of spike mutations on SARS-CoV-2 neutralization.
    Rees-Spear C; Muir L; Griffith SA; Heaney J; Aldon Y; Snitselaar JL; Thomas P; Graham C; Seow J; Lee N; Rosa A; Roustan C; Houlihan CF; Sanders RW; Gupta RK; Cherepanov P; Stauss HJ; Nastouli E; ; Doores KJ; van Gils MJ; McCoy LE
    Cell Rep; 2021 Mar; 34(12):108890. PubMed ID: 33713594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.
    Liu L; Iketani S; Guo Y; Chan JF; Wang M; Liu L; Luo Y; Chu H; Huang Y; Nair MS; Yu J; Chik KK; Yuen TT; Yoon C; To KK; Chen H; Yin MT; Sobieszczyk ME; Huang Y; Wang HH; Sheng Z; Yuen KY; Ho DD
    Nature; 2022 Feb; 602(7898):676-681. PubMed ID: 35016198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
    Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
    Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.
    Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ
    PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Bowen JE; Rosen LE; Saliba C; Zepeda SK; Culap K; Pinto D; VanBlargan LA; De Marco A; di Iulio J; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà PE; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Snell G; Veesler D; Corti D
    Nature; 2022 Feb; 602(7898):664-670. PubMed ID: 35016195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
    Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
    Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
    Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G
    Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.
    Greaney AJ; Starr TN; Barnes CO; Weisblum Y; Schmidt F; Caskey M; Gaebler C; Cho A; Agudelo M; Finkin S; Wang Z; Poston D; Muecksch F; Hatziioannou T; Bieniasz PD; Robbiani DF; Nussenzweig MC; Bjorkman PJ; Bloom JD
    Nat Commun; 2021 Jul; 12(1):4196. PubMed ID: 34234131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain.
    Nabel KG; Clark SA; Shankar S; Pan J; Clark LE; Yang P; Coscia A; McKay LGA; Varnum HH; Brusic V; Tolan NV; Zhou G; Desjardins M; Turbett SE; Kanjilal S; Sherman AC; Dighe A; LaRocque RC; Ryan ET; Tylek C; Cohen-Solal JF; Darcy AT; Tavella D; Clabbers A; Fan Y; Griffiths A; Correia IR; Seagal J; Baden LR; Charles RC; Abraham J
    Science; 2022 Jan; 375(6578):eabl6251. PubMed ID: 34855508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.